How to deliver winning brand propositions that can pay huge dividends
Resources and News
FEATURED
Latest from Prescient
-
What should developers consider to ensure both market success and the greatest public good? -
The Pharma CI Europe 2023 Conference will be held on March 30-31, 2023, in Rome, Italy.
;
Looking forward to meeting you at #PharmaCI Europe 2023 in Rome on March 30-31! Don't miss the opportunity to attend our session on "Strategic Insights to Influence Medical and Commercial Planning" by Dr. Cameron Mackenzie & Easha Ghildyal. More info at https://hubs.ly/Q01JxC160
Prescient announces the recent appointments of Navi Singh Parmar, Dr. Sanam Sikander-Rehman and Michaela Scheiner to its Medical team. Read more in our press release: https://hubs.ly/Q01Jns5b0
Resources & News
Filter Categories
All
Event
Blog Post
White Paper
Case Study
Press Release
In The News
-
What should developers consider to ensure both market success and the greatest public good?
-
The Pharma CI Europe 2023 Conference will be held on March 30-31, 2023, in Rome, Italy.
-
We are proud to announce that Katy Chun has been recognized as a Healthcare Businesswomen’s Association (HBA) 2023 Rising... -
Prescient hires three new senior members to support its growing Medical Center of Excellence. -
Diane Whelan, Head of Learning and Development at Prescient, will present at the 23rd People Development Summit in Sitges,... -
Our colleague Sabina Zikmundova held an EU-funded workshop on menstruation and female health for youth workers in Georgia to... -
In partnership with MAPS, Prescient will moderate a webinar on Friday, January 27, 2023, at 10:00 AM EDT. -
Jamie Denison-Pender moves into corporate development role as Dr. Debasish Talukdar becomes the new Chief Executive Officer. -
Deep-dive into the evolving JAK Paradigm with special focus on topicals -
How to deliver winning brand propositions that can pay huge dividends -
Now in its fourth year, Prescient’s research study on strategic imperatives in CI collects feedback from thought leaders across... -
The Pharma CI USA 2022 Conference will be held September 21-22, 2022, in Newark, US. -
The Prescient Academy creates a culture of lifelong learning and development that enables Prescient team members to grow their... -
How did CI survive COVID-19? An analysis of how the CI function emerged from the depths of a pandemic -
The current late-stage pipeline is driving intense competition for patient share -
Physicians and Pharma need to understand why this fast-developing technology will transform routine screening and modernize the adjuvant setting -
Prescient hires two new senior members and opens an office in Barcelona. -
This blog looks at the critical success factors of a ‘good’ LCM plan and the learnings from success stories... -
PLOS Medicine has published an article by Prescient’s Ivan Zhelyazkov. -
With the improvement of MM treatments, physicians and healthcare providers must respond to the new needs of long-term survivors. -
We are pleased to announce that Strategic North is a finalist in the Best Patient-Centric Approach category for the... -
The MAPS EMEA 2022 Annual Meeting will be held May 15-17, 2022, Paris, France. -
In this white paper, Prescient sets out a roadmap for Medical Affairs launch excellence strategy to boost a product’s... -
The 2022 Healthcare Businesswomen’s Association Woman of the Year Luncheon will be held on May 10 at the New... -
We are delighted to announce that Jeanne Penn is being recognized as a 2022 HBA Luminary Award winner. Jeanne... -
Prescient announces the recent acquisition of Strategic North, a global commercial strategy consultancy that partners with a wide range... -
The 2022 Biocom Global Life Sciences Partnering Conference will be held from February 22 to 24, 2022 in San... -
Prescient announces the recent appointments of Shirin Ahmed, Dr. Erica Carlisle and Dr. Christian Wasmer as leaders in the... -
Highly competitive markets require different thinking for an asset to succeed. As landscapes expand to more players and evolve... -
China represents huge opportunities – and risks. Prescient has gathered thought leaders for a roundtable discussion on the approaches... -
The European market has opportunities, but the wrong approach could leave value on the table. Prescient’s guide will steer... -
Prescient grows its global footprint in Europe with the opening of locations in Munich and Madrid. -
The third annual white paper on the strategic imperatives in CI is out now. Competitive intelligence (CI) is fundamental... -
COVID-19 has revolutionized the use of sophisticated technologies in drug development -
Pharma has been slow to fully utilize technology in processes and decision-making. The swift development of COVID-19 vaccinations has... -
Non-medical switching (NMS) seems attractive on paper but often leads to poor clinical outcomes and higher overall costs to... -
Medical Affairs (MA) is a “sleeping giant” with potential to offer companies significant strategic value. While MA has occasionally... -
Nature has accepted and published research by Prescient’s Amol Padgaonkar. -
Competitive Intelligence (CI) is fundamental to ensuring the success of pharmaceutical companies, whether they are planning a new drug... -
Prescient hires Gerald Dunstan as Chief Strategy Officer to execute the company’s growth strategy. -
Our Prescient spirit is built on pride and passion for science, intellectual curiosity, and a joint commitment to achievement.... -
Prescient’s Anna Graca has published an article in GLIA. -
Prescient’s Anuj Gupta has published an article in Economic Times. -
A webinar exploring the potential for CI practitioners to boost their businesses and careers -
Early insights on emerging trends in Europe for 2021-2022. -
Prescient’s Andrea Campi’s doctoral research has yielded a published article in Bone. -
The slow uptake of biosimilars in the US market may have lulled some into a false belief that they... -
Prescient hires two new senior members to expand its expertise and keep pace with the company’s growth. -
Pharma leaders need to understand the factors holding assets back from reaching full potential and keep a sense of... -
The Journal of Health Policy and Economics has accepted and published research from Prescient’s Marselia Tan. -
While all global biopharma has had to respond to COVID, UK domiciled biopharma is also faced with the long-term... -
In this first of two blogs Nick Turner, Senior Director at Prescient Healthcare Group looks at how COVID is... -
Prescient announces the recent appointment of two new senior members: Emma Leung and Matt Majer. -
Alzheimer’s disease (AD) is a neurodegenerative disease characterized by loss of cognitive function (specifically memory loss) and inability to... -
The unmet need in AML continues to be quite high despite the advances in cancer research. -
Prescient announces the recent appointment of two new senior members: Emma Leung and Matt Majer. -
Prescient Healthcare Group has been recognized, for the fourth year in a row, as one of the 50 fastest-growing... -
Innovative brands need to revisit their biosimilar plans to ensure they can maximize their time over the competition -
Most of the therapeutic candidates target rare diseases and cancers which are difficult to treat and do not have... -
Cell Chemical Biology has accepted and published research from Prescient’s Syed Meheboob Ahmed: -
The slowdown of recent growth in the Chinese Pharma market demonstrates potential for western companies to partner with their... -
Digital health can speed the identification and approval of agents in oncology, rare diseases, immunology and neurology. -
Prescient Healthcare Group announced today that Bridgepoint Development Capital, part of Bridgepoint, the international alternative asset management group, has... -
As ADCs continue to get incorporated in the treatment landscape across several solid tumors, data emerging from the next... -
Chinese pharmaceutical companies present both an opportunity and a threat to their international counterparts. In this blog, we explore... -
The Chinese regulatory landscape is very different compared to that of the rest of the world. Can businesses bridge... -
Prescient looks at the critical data presented at the American Society of Hematology (ASH) Annual Meeting and how they... -
Prescient looks at the critical data presented at the American Society of Hematology (ASH) Annual Meeting and how they... -
Prescient looks at the critical data presented at the American Society of Hematology (ASH) Annual Meeting and how they... -
Prescient looks at the critical data presented at the American Society of Hematology (ASH) Annual Meeting and how they... -
Nature has accepted and published a manuscript from Prescient’s Aakriti Verma in their “Scientific Reports”. This research revealed novel... -
Last year, Prescient embarked upon the ambitious exercise of interviewing competitive intelligence (CI) practitioners across the pharmaceutical industry to... -
Prescient hires three new senior members to expand its expertise and keep pace with the company's growth. Gordon Gochenauer,... -
How you spend your CI budget is as important as how much you are spending; therefore, it is vital... -
Competitive intelligence (CI) is fundamental to ensuring the success of pharmaceutical companies, whether they are planning a new drug... -
In this white paper, Ben Doran and Jeanne Penn draw on their experiences in the pharmaceutical field to explain... -
Among the available cancer treatments, pembrolizumab is an industry bellwether: A drug that is as close to a “silver... -
October 21, 2020, marks the Carnegie Council’s Global Ethics Day, but as far as Prescient is concerned, every day... -
New product planning fails more often than it succeeds. Prescient’s Global Head of Advisory looks at why this happens... -
The 2020 Annual Ph.D. to Consulting (PTC) Conference will be a virtual event held on September 25, 2020. -
In partnership with Biocom, Prescient will present a webinar on October 22 to October 27 at 11:00 AM PDT. -
The 2020 Baird Global Healthcare Conference will be held virtually on September 9-10, 2020. -
Prescient will be attending the virtual 2020 Pharma CI USA Conference and Exhibition on September 29-October 1, 2020. -
Virtual workshops have different planning requirements compared to similar events that might take place face to face. Prescient has... -
Virtual workshops have different planning requirements compared to similar events that might take place face to face. Prescient has... -
In our previous blog, COVID’s impact on the Pharma industry, we highlighted the major macroeconomic factors that are shaping... -
The COVID-19 pandemic poses the greatest public health emergency for 100 years, coupling high infectivity with a case mortality... -
Prescient announces the recent appointment of two new senior members, Peter Donachie and Dr. Haroon Khan, to its Advisory... -
Prescient announces the recent appointment of three new senior members to its Intelligence & Insight business: Dr. Anuj Gupta,... -
Pharma in the post-COVID era – adapting to the new normal is the latest whitepaper from Prescient, providing a... -
Now more than ever, we are facing the question of why we need digital media monitoring (DMM). Competitors are... -
In partnership with Biocom, Prescient will be presenting a webinar on Wednesday, August 8 at 1:00 PM PT. -
Prescient’s thought leaders address major shifts in the landscape and outline near-, medium- and long-term choices facing pharma strategy... -
The impact of COVID-19 on clinical and regulatory affairs, manufacturing and supply chains, and stakeholder engagements has slowed the... -
Regulatory agencies across the world are issuing flexible guidelines to cater to the COVID-19 public health emergency. This is... -
Content and offerings are evolving – so should your approach to maximize insights. -
Charles Darwin would have been fascinated to sit back and observe how our society evolves to cope with the... -
Do you feel that without a physical congress, you are losing an essential tool in understanding the dynamics of... -
The continued rise of COVID-19 is expected to have short- and long-term impacts across the key biopharmaceutical functions, and... -
Prescient Healthcare Group has been recognized, for the third year in a row, as one of the 50 fastest-growing... -
Prescient’s Dr. Julia Seaman shares her thoughts on monitoring COVID-19 in the American Society for Quality’s March issue of... -
Prescient is proud to share the exciting news that we will be officially opening a Boston office! -
Prescient will be in Zurich for the 2020 Pharma CI Europe Conference and Exhibition on March 19-20, 2020.On Thursday,... -
Prescient announces the recent appointment of two new senior members, Kevin Baruzzi and Dr. Arun Shrivats, to its Advisory... -
Prescient, a biopharma product and portfolio strategy partner, announces the recent appointment of three new senior members to its... -
The 2020 Biocom Global Life Sciences Partnering Conference will be held from February 25 to 27, 2020 in La... -
Prescient has conducted research among competitive intelligence (CI) stakeholders throughout the biopharmaceutical industry to identify the top challenges in... -
Prescient’s Andrea Campi’s doctoral research has yielded a published manuscript in Connective Tissue Research: Mechanosensitive Ca2+ signaling and coordination is... -
Too Big to Ignore: What CI Needs to Do to Make the China Market Manageable Chinese pharmaceutical companies present both... -
The American Society of Gene and Cell Therapy has accepted and published a manuscript from Prescient’s Carly Jones in... -
LeadingBiotech’s East/West CEO will be held during January 11-12, 2020, in San Francisco. The event brings together global leaders... -
In this white paper, Prescient has identified three industry trends that are shaping competitive dynamics in the US market... -
Tumor mutational burden (TMB (the number of mutations per megabase of DNA (mut/Mb)) can be a predictor of response... -
Prescient’s Andrea Campi has been recognized with the ASBMR Young Investigator Award. The American Society for Bone and Mineral Research...
-
The 2019 annual Pharma CiMi.CON will be held on November 7-8 in Boston. Dr. Mark Little will attend this... -
Prescient will be in Boston, MA, for the 2019 New Product Planning Summit on December 2-3, 2019. On December 2...
-
The Biocom Q4 2019 Deal Makers Reception Awards will be held on Thursday, December 12, in La Jolla, California....
-
The 2019 FierceBiotech Drug Development Forum will be held on October 28-29, 2019, in Boston. Dr. Mark Little will...
-
The European Society of Cardiology has accepted and published a manuscript from Prescient's Carly Jones in Cardiovascular Research: A novel...
-
The 2019 Annual Ph.D. to Consulting (PTC) Conference will be held on September 20, 2019, in London. The conference... -
The 2019 Baird Global Healthcare Conference will be held on September 4-5, 2019, in New York. Dr. Paul Harney... -
The Institute for the Study of Business Markets (ISBM)'s Driving Marketing Excellence and Strategic Insights for B2B event will... -
Prescient will be in Newark, NJ, for the 2019 Pharma CI USA Conference and Exhibition on September 18-19, 2019. On... -
Skin diseases constitute one of the leading causes of health burden worldwide, measured as disability-adjusted life years (DALYs). Among... -
The BIO International Convention will be held June 3-6, in Philadelphia, PA. The event attracts 16,000+ biotechnology and pharma... -
LeadingBiotech's Boston CEO will be held on May 28-29. The event brings together past, present and future leaders in...
-
ExL Events’ Medical Affairs Strategic Summit (MASS) will be held April 24-26 in Morristown, NJ. The event addresses the... -
LeadingBiotech's Cancer Advance Boston will be held on April 24. The event brings together past, present and future leaders...
-
Featuring quotes from EMEA President, Dr. Rakesh Verma In this article by Consultancy.uk, Dr. Rakesh Verma discusses how we advise... -
Prescient Healthcare Group has been recognized, for the second year in a row, as one of the 50 fastest-growing... -
Sidnee Pinho, Prescient's US Chief Operating Officer, led a workshop at Rutgers University on February 1, 2019. Sidnee Pinho began the... -
The 2019 Spring MedAffairs Leaders Forum will be held February 26-28, 2019, in London. This event brings together senior decision-makers...
-
The 2019 Biocom Global Life Science Partnering Conference will be held February 26-28, 2019, in La Jolla. The event...
-
Prescient will be in Basel for the 2019 Pharma CI Europe Conference and Exhibition on March 5-6, 2019. On March... -
LeadingBiotech's East/West CEO will be held January 5-6, 2019, in San Francisco. The event brings together global leaders in...
-
Activating mutations in the EGFR gene are found in about 10-12% of all non-small cell lung cancer (NSCLC) cases... -
Lung cancer is the leading cause of cancer mortality worldwide, accounting for more than 1.6 million deaths annually. Non-small...
-
The Biocom Q4 2018 Deal Makers Reception Awards will be held on Thursday, December 13, in La Jolla, California....
-
The CLSA 15th Annual Pantheon 2018 – Presenting DiNA™ Awards will be held on Friday, November 30, 2018, in...
-
Prescient will be in Boston, MA for the 2018 New Product Planning (NPP) Summit on December 12-13, 2018. On December...
-
Breast cancer is the most common cancer in women with more than 2.1 million new cases diagnosed in 2018.... -
With regulatory approval, CAR-T cell therapy must address significant unmet needs in clinical practice without restrictions in order to... -
The 18th Annual Biotech in Europe Forum, organized by Sachs Associates, will be held October 4-5, 2018, in Basel, Switzerland....
-
Featuring quotes from Dr. Paul Harney, President – North America, and Ben Druck, Principal. In this article by Medical Marketing... -
A largely glossed-over finding from active-controlled trials of checkpoint inhibitors in solid tumors is the delayed crossover of Kaplan-Meier...
-
The 4th Annual CAR-TCR Summit 2018 – Changing Lives with CAR-T & TCR Cell Immunotherapies, organized by Hanson Wade, will...
-
The Baird's 2018 Global Healthcare Conference will be held September 5-6, 2018, in New York. Dr. Paul Harney and...
-
Prescient will be in Newark, NJ for the 2018 Pharma CI USA Conference and Exhibition on September 26-27, 2018. On...
-
Our client was a global biopharmaceutical company with a market-leading brand more than 20 years’ old. It came under... -
Our global pharmaceutical client had a product whose patent was expiring within a year. The client wanted to understand... -
Our client, a European specialty pharmaceutical company, was considering an expansion of indications within its target therapeutic group via... -
Prescient Healthcare Group, a biopharmaceutical product and portfolio strategy firm, announces the recent appointment of Dr. Paul Harney as... -
Ben Doran has been recognized for the "40 Under 40 in Cancer" Award. This award celebrates the contributions of young oncology professionals... -
Access to cancer therapies is a part of every country’s health policy agenda; it, however, is not guaranteed to... -
Prescient is committed to respecting our clients’ privacy and personal data. Over the past few months, we have audited... -
Featuring quotes by Dr. Rakesh Verma, President, EMEA & APAC Big pharma companies are increasingly reliant on consultants to communicate... -
Our global pharmaceutical client was developing a suite of biosimilars that it intended to commercialize in several Latin American... -
By: Tanya Casimiro, PhDAs the first Phase III data in non-alcoholic steatohepatitis (NASH) begin to be released, the next... -
Prescient will be in London for the 2018 SMi Annual Pain Therapeutics Conference on May 21-23, 2018. On May 23,...
-
There is significant interest in companion diagnostics (CDx) throughout the healthcare industry, but for this personalized medicine approach to... -
Approximately 7,000 rare diseases affect more than 300 million people worldwide, or around 5-8% of the population, depending on... -
On April 16, 2018, data from multiple pivotal trials in first-line (1L) non-small-cell lung cancer (NSCLC) were presented at... -
Our client, a global pharmaceutical company, was in the process of strengthening the vision for its future product portfolio. -
Our global pharmaceutical client’s mature product was two years away from patent expiry in its key regulated markets and... -
The US healthcare system has been facing great uncertainty, with ongoing challenges to the sustainability of the Affordable Care... -
Prescient Healthcare Group has been recognized as one of the 50 fastest-growing companies in 2017. We have been ranked...
-
Prescient Healthcare Group, a global product strategy and decision support consultancy, announces the recent appointment of Dr. Debasish Talukdar... -
Our client, a global pharmaceutical company, sought to decide whether to progress two internal assets into Phase III development... -
Quotes by: Jamie Denison-Pender, CEO, Prescient. Jamie provides Prescient’s views of the industry and market conditions. This report brings together...
-
Prescient will be in Lisbon, Portugal for the 2018 Pharma CI Europe Conference and Exhibition on February 27-28. Joanne Taylor,... -
Prescient Healthcare Group, a global product strategy and decision support consultancy, announces the recent appointments of Nick Edwards and... -
Our client, a global pharmaceutical company, planned to launch a new product about six months ahead of a direct... -
Our client, a global pharmaceutical company, wanted to devise a global strategy to proactively address threats from the launch... -
Our client, a global pharmaceutical company, needed to identify opportunities in the EU5 countries for a first-in-class injectable product... -
Our client, a global specialty pharmaceutical company, was seeking to evaluate the clinical and commercial attractiveness of a potential... -
Baird’s 10th annual Global Healthcare Conference was held in New York on September 6-7, 2017 and featured nearly 100...
-
Prescient will be in Dusseldorf, Germany for the 2017 Pharma Market Research Conference (PMRC) Europe on October 24-25, 2017.... -
Our client was developing a novel cellular therapy with promising Phase I safety data and some evidence of efficacy...
-
Our client, a global pharmaceutical company, was planning to launch its first-ever biosimilar for the treatment of inflammatory conditions.
-
Our global pharmaceutical client needed a long-term partner who could deliver evidence-based insights to support the clinical, commercial and... -
Baird Capital, the direct investment arm of Robert W. Baird & Co., announced today that it has acquired an...
-
Our global pharmaceutical client had an immunotherapy in early-stage clinical development.
-
Our global pharmaceutical client needed to prioritize launch regions for a biosimilar in a large and growing therapeutic area...
-
Our client, a global pharmaceutical company, had a drug in development for a disease area dominated by high-efficacy drugs...
-
Our client, a global pharmaceutical company, was planning to launch a second-in-class biologic in a crowded market space.
-
Our global pharmaceutical client needed insights into the then-unknown biosimilars space and assistance in successfully defending its franchises.
-
Our global pharmaceutical client’s drug had one of the most successful launches in its category and monopolized the market...
-
Due to the increase in incidence of a particular disease worldwide, our client, a global pharmaceutical company, wanted to...
-
Our client, a global pharmaceutical company, was planning to launch an immunology agent.
-
Our client, a global pharmaceutical company, had a biologic in development for the treatment of a condition with a...
-
Years of non-small cell lung cancer (NSCLC) research are beginning to result in significant gains in the standard of...
-
Prescient assessed opportunities across patient segments to guide our client’s go-to-market strategies. -
Prescient developed a five-year forecast of potential cellular therapy patients to guide our client’s treatment center qualification strategy. -
Prescient conducted a situational analysis of the immunology market to identify high-impact trends and evolving HCP prescribing behaviors to... -
Prescient helped accelerate, assure and simplify the client’s annual medical affairs strategic planning across its solid tumor franchise. -
Prescient conducted an in-depth analysis of competitor global medical affairs teams to understand best practices in the industry. -
Prescient developed a BD assessment framework to identify attractive candidates in an oncology indication with a high unmet need.
LinkedIn
Twitter
Facebook